- In early April 2026, Synchrony announced that CareCredit cardholders can now use their health and wellness credit card for eligible purchases on Walmart.com, adding new categories such as medical supplies, fitness equipment, sleep products, and pet care to its already wide acceptance in Walmart, Sam’s Club, and more than 290,000 health-related locations.
- By pairing this expanded CareCredit access with fresh financial literacy grants for K–12 teachers and schools, Synchrony is broadening both its practical reach in everyday health spending and its role in consumer financial education.
- We’ll now examine how expanding CareCredit’s reach to Walmart.com could influence Synchrony’s investment narrative around health and wellness financing.
AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Synchrony Financial Investment Narrative Recap
To own Synchrony, you need to believe that its partnerships and digital capabilities can keep private label and co‑brand cards relevant as payments shift online, while credit quality and regulatory costs remain manageable. The CareCredit expansion on Walmart.com modestly supports the near term catalyst of growing health and wellness receivables, but it does not remove key risks around partner concentration and pressure from newer payment models.
The most directly related announcement is CareCredit’s broader integration across health providers, such as recent platform deals with Planet DDS and Weave. Together with Walmart.com, these moves point to a consistent effort to embed CareCredit in everyday medical, dental, and pet spending, which could reinforce the growth catalyst in health and wellness financing if volumes respond as expected.
Yet investors should also weigh how much partner concentration and newer payment options could matter if...
Read the full narrative on Synchrony Financial (it's free!)
Synchrony Financial's narrative projects $16.5 billion revenue and $3.3 billion earnings by 2028.
Uncover how Synchrony Financial's forecasts yield a $90.26 fair value, a 25% upside to its current price.
Exploring Other Perspectives
Compared with the baseline view, the most optimistic analysts were already assuming revenue could reach about US$17.2 billion and earnings US$3.4 billion by 2028, so this Walmart.com news may either support that upbeat case around embedded health financing or highlight how much depends on whether traditional card driven models can withstand the shift toward Buy Now Pay Later.
Explore 8 other fair value estimates on Synchrony Financial - why the stock might be worth just $71.25!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Synchrony Financial research is our analysis highlighting 5 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Synchrony Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synchrony Financial's overall financial health at a glance.
Want Some Alternatives?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Find 64 companies with promising cash flow potential yet trading below their fair value.
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com